


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B31

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 231/54, 303/32, C07C 317/24		A2	(11) International Publication Number: WO 98/22442
			(43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/EP97/06398		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 November 1997 (12.11.97)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: MI96A002385 15 November 1996 (15.11.96) IT			
(71) Applicant (for all designated States except US): ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE [IT/IT]; Piazzale della Stazione, I-00040 S. Palomba - Pomezia (IT).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GIANNANGELI, Marilena [IT/IT]; Via Clelia, 88, I-00181 Roma (IT). TOMASELLI, Mauro [IT/IT]; Via Leibniz, 28, I-00137 Roma (IT). PINZA, Mario [IT/IT]; Via per Cesano Boscone, 24, I-20094 Corsico (IT).			
(74) Agents: MARCHI, Massimo et al.; Marchi & Partners s.r.l., Via Pirelli, 19, I-20124 Milano (IT).			
(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING DIARYL-CYCLOMETHYLENOPYRAZOLE COMPOUNDS AND THEIR USE AS CYCLOOXYGENASE I (COX I) INHIBITORS			
(57) Abstract			
<p>A pharmaceutical composition comprising a diaryl-cyclomethylenpyrazole compound of formula (I) wherein n is 0, 1, 2 or 3; R, R' and R'', equal to or different from each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.</p>		 <p>(I)</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

PHARMACEUTICAL COMPOSITIONS COMPRISING DIARYL-CYCLOMETHYLENOPYRAZOLE COMPOUNDS AND THEIR USE AS CYCLOOXYGENASE 1 (COX 1) INHIBITORS

The present invention relates to pharmaceutical compositions comprising a diaryl-cyclomethylenpyrazole compound endowed with anti-inflammatory, analgesic and antipyretic activity, the process for the preparation of said diaryl-cyclomethylenpyrazole compounds and some novel diaryl-cyclomethylenpyrazole compounds thus obtained.

More particularly, the present invention relates to a pharmaceutical composition comprising a diaryl-cyclomethylenpyrazole of general formula



(I)

wherein

n is 0, 1, 2 or 3;

R , R' and R'' , equal or different each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl,

or a pharmaceutically acceptable salt thereof,

together with at least a pharmaceutically acceptable carrier.

It is known that non-steroidal anti-inflammatory drugs, usually used for treating inflammation, pain and fever exhibit their major activity by inhibiting the cyclooxygenase enzyme (COX).

Recently, two isoforms of the enzyme have been found: the first one (COX1) is constitutively expressed in a large variety of cells while the

- 2 -

second one (COX2) is rapidly induced in several type of cells by agents such as endotoxines and cytokines.

The constitutive form COX1 is responsible in large part of the basal endogenous release of prostaglandins that promote physiological actions such as maintaining the gastrointestinal integrity or the renal blood flux.


On the contrary, the inducible form COX2 is likely responsible of the production of prostaglandins in replay to pro-inflammatory stimuli in different type of tissues and cells.

For this reasons, the person skilled in the art opines that a selective inhibitor of COX2 has anti-inflammatory properties like to a conventional non-steroid anti-inflammatory, however with reduced ulcerogenic and nephrotoxic action. A short description of the potential utilities of COX2 inhibitors is given in the article by J.Vane in "Nature", 367, 215-216, 1994, and in an article on "Drugs News and Prospectives", 7, 501-512, 1994.

Now, it has been found that the compounds of formula (I) are provided with high selectivity towards COX2.

Some diaryl-cyclomethylenpyrazoles of formula (I) are novel.

It is therefore a second object of the present invention to provide a diaryl-cyclomethylenpyrazole of formula (Ia)



(Ia)

wherein

n is 0, 1, 2 and 3;

- 3 -

R, R' and R'', equal or different each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl, or pharmaceutically acceptable salts thereof, provided, however, that


- a) when n is 1, and two of R, R' and R'' are hydrogen, the third is not hydrogen or chlorine; and
- b) when n is 3, at least one of R, R' and R'' is not hydrogen.

Preferably, n is 0, 1 or 2.


Examples of preferred halogens are fluorine and chlorine.

Preferably, the alkyl chain of the alkylsulphonyl and alkylamino sulphonyl has of from 1 to 6 and, more preferably, of from 1 to 3 carbons and may be linear, branched or cyclic. Typical examples of such substituents are methysulphonyl, methylaminosulphonyl and cyclopropylsulphonyl.

A third object of the present invention is to provide a process for manufacturing a compound of formula (I), characterized in that a compound of formula




wherein X is H or cyclohexyliden, and R has the above mentioned meanings, is reacted with a compound of formula



wherein R' and R'' have the above mentioned meanings and A is selected from the group comprising COHal, A', A'' and A'''

- 4 -




wherein Hal is halogen, preferably chlorine.

Preferably, when X = H, this reaction is carried out in a solution of a suitable polar diluent and in the presence of an organic or mineral acid at a temperature of from 0 to 120°C. Preferably, of from 60 to 80°C. Typical examples of preferred diluents are lower aliphatic alcohols.

When A = A' and X is hydrogen, the reaction is preferably carried out in a solution of a lower alcohol, preferably ethyl alcohol, in the presence of an acid, preferably glacial acetic acid, according to A.J. Nunn and F.J. Rowell in "J. Chem. Soc.", 23, 2435-8, 1975, to give directly the desired compound of formula (I).

In turn, when A = A'' and X is hydrogen, the reaction is preferably carried out in a solution of a lower alcohol, preferably ethyl alcohol, in the presence of an acid, preferably sulphuric acid, to give, as main product, the desired compound of formula (I).

Finally, when A = A''' and X is hydrogen, the reaction is preferably carried out in a solution of a lower alcohol, preferably ethyl alcohol, in the presence of an acid, preferably hydrochloric acid, to give the compound of formula



from which the corresponding compound of formula (I) is prepared by treating with a weak oxidant, such as bromine in water, according to the method described in J. Chin. Chem. Soc., 41, 585-9, 1994, or with manganese bioxide in a solution of methylenechloride.


The compound of formula (IV) wherein $n = 1$, $R = \text{methylsulphonyl}$, $R' = \text{H}$ and $R'' = \text{Cl}$ is novel. Therefore, it is a further object of the present invention.

When A is COHal and X is cyclohexylidene, the reaction is preferably carried out in the presence of anhydrous tetrahydrofuran at a temperature of from -70 to 20°C to give directly the compound of formula (I).

The intermediate compounds of formula (III) wherein A is A' , R' is H and R'' is alkylsulphonyl, preferably methylsulphonyl, or fluorine, the compound wherein A is A' , R' and R'' are halogen, preferably chlorine and fluorine, and the compound of formula (III) wherein $A = A'''$, $R' = \text{H}$ and R'' is alkylsulphonyl, preferably methylsulphonyl, are new.

Therefore, they are a further object of the present invention.

The new compounds of formula (III) wherein A is A''' and R' and R'' have the above mentioned meanings, are preferably prepared by dehydration of the compound of formula



The compound of formula (V), wherein R' is H and R'' is alkylsulphonyl, preferably methylsulphonyl, is also new and it is a further object of the present invention.

Typical examples of diseases which might benefit from the treatment with a pharmaceutical composition according to the present invention

are the inflammatory diseases such as, for example, Alzheimer disease, ulcerative colitis and colon tumor.

Preferably, the pharmaceutical compositions of this invention are prepared in a suitable dosage form comprising an effective dose of at least a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least an inert pharmaceutically acceptable carrier.

Examples of suitable dosage forms are tablets, capsules, coated tablets, granules, liposomes, solutions and syrups for oral administration; creams, liposomes, ointments and medicated patches for topical administration; suppositories for rectal administration and sterile solutions for injectable, aerosolic and ophthalmic administration.

The dosage forms may also contain other conventional ingredients such as: preservatives, stabilizers, surface-active agents, buffers, salts for the regulation of the osmotic pressure, emulsifiers, sweeteners, colouring agents, flavouring agents and the like.

When required by particular therapies, the pharmaceutical composition of the present invention may contain other pharmacologically active ingredients whose concomitant administration is therapeutically useful.

The amount of the compound of formula (I) or of a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the present invention may vary in a rather wide range depending on known factors such as, for instance, the type of disease to be treated, the severity of the disease, the body weight of the patient, the dosage form, the chosen route of administration, the number of dosage forms administered daily and the efficacy of the chosen compound of formula (I). However, the optimum amount may be easily and routinely determined by a person skilled in the art.

Typically, the amount of the compound of formula (I) or of a pharmaceutically acceptable salt thereof in the pharmaceutical composition of

- 7 -

the present invention will be such that it insures an administration level of from 0.01 to 140 mg/Kg/day.

The dosage forms of the pharmaceutical composition of the present invention can be prepared according to techniques which are known to the pharmaceutical chemist and comprise procedures such as mixing, granulation, compression, solubilization, sterilization and the like.

The following examples are intended to illustrate the present invention without limiting it in any way.

EXAMPLE 1

Preparation of 2-(α -hydroxy-4-methylsulphonylbenzyl) cyclohexanone

(V: R' = H, R'' = SO₂CH₃)

An aqueous solution (20.6 ml) of sodium carbonate (1.89 g, 0.018 mole) was added dropwise to a mixture of 4-methylsulphonylbenzaldehyde (2.21 g, 0.012 mole) and cyclohexanone (4.7 g, 0.048 mole) at room temperature. After 10 minutes at room temperature, the reaction mixture was diluted with water (135 ml) and allowed to stand for 6 additional hours. The solid precipitated was filtered and crystallized from ethyl acetate, obtaining 2 g of the desired product (m.p. 150-152°C).

Elemental analysis	C	H
% found:	59.42	6.35
% calculated: for C ₁₄ H ₁₈ O ₄ S	59.56	6.43
¹ H-NMR (δ , CDCl ₃): 1.5-2.7 (m, 9H); 3.08 (s, 4H); 5.46 (m, 1H); 7.5 (d, 2H); 7.8 (d, 2H).		

EXAMPLE 2

Preparation of 2-(4-methylsulphonyl)benzylidencyclohexanone

(III: A = A'', R' = H, R'' = SO₂CH₃)

A solution of 2-(α -hydroxy-4-methylsulphonylbenzyl) cyclohexanone (4.84 g, 0.017 mole) in absolute ethyl alcohol (9.7 ml), added with one drop of concentrate HCl, was heated up to the reflux temperature. After some minutes, it was cooled, diluted by an equal volume of water and

- 8 -

extracted with dichloromethane (2x10 ml). After evaporation of the solvent under reduced pressure, the residual was chromatographed on a flash column, eluting with a mixture of toluene:ethyl acetate 4:1. Yield, 1.33 g (m.p. 89-90°C).

Elemental analysis	C	H
% found:	63.45	6.17
% calculated: for C ₁₄ H ₁₆ O ₃ S	63.62	6.10

¹H-NMR (δ, CDCl₃): 1.7-2.2 (m, 4H); 2.5-2.9 (m, 4H); 3.08 (s, 3H); 7.5-7.7 (m, 3H); 7.8-8.1 (d, 2H).

EXAMPLE 3

Preparation of 2-(4-methylsulphonyl)phenyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydroindazole (AFR 906)

(I: n = 1, R = SO₂CH₃, R' = H, R'' = Cl)

a) Glacial acetic acid (15 ml) was quickly dropped under stirring and at room temperature into a suspension of 4-methylsulphonylphenyl hydrazine (7.3 g, 0.039 mole) and 2'-(4-chlorophenyl)spiro [cyclohexane-2'-oxiran]-2-one (9.2 g, 0.039 mole) in absolute ethyl alcohol (400 ml). Then, the reaction mixture was heated at reflux for 4 hours. The solvents were removed under reduced pressure and the residue was crystallized two times from ethyl alcohol. Yield, 11.4 g (m.p. 153-155°C).

Further preparations of AFR 906 performed as described above melted at 176-178°C. Under microscope, the compound melting at 153-155°C proved to be in form of birefractive prismatic tablets, while the compound melting at 176-178°C was in form of non-refractive microcrystals.

Elemental analysis	C	H	N
% found:	61.93	4.81	7.12
% calculated: for C ₂₀ H ₁₉ ClN ₂ O ₂ S	62.08	4.95	7.24

- 9 -

¹H-NMR (δ, DMSO): 1.6-1.9 (m, 4H); 2.4-2.7 (m, 4H); 3.25 (s, 3H); 7.1-7.6 (m, 6H); 7.8 (d, 2H).

- b) Condensation of 2-(4-chlorobenzoyl)cyclohexanone with 4-methylsulphonylphenylhydrazine afforded a mixture that was separated by column chromatography to give, as main product, the compound mentioned in paragraph a) above.
- c) Oxidation, preferably with MnO₂, in solution of CH₂Cl₂ of the compound of the Example 7 (AFR 109).

By working in a way similar to that described above may be prepared the following compounds:

AFR 206: 2-(4-methylsulphonyl)phenyl-3-(4-chlorophenyl)-4,5,6,7,8-2H-pentahydrocycloheptapyrazole (I: n = 2, R = SO₂Me, R' = H, R'' = Cl), m.p. 171-3°C (hexane-ethyl acetate)

AFR 207: 2-(4-aminosulphonyl)phenyl-3-(4-chlorophenyl)-4,5,6,7,8-2H-pentahydrocycloheptapyrazole (I: n = 2, R = SO₂NH₂, R' = H, R'' = Cl), m.p. 200-1°C (hexane-ethyl acetate)

AFR 209: 2-(4-cyclopropylsulphonyl)phenyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydroindazole (I: n = 1, R = cyclopropyl-SO₂, R' = H, R'' = Cl), m.p. 136-8°C (ethanol)

AFR 402: 2-(4-methylsulphonyl)phenyl-3-(4-chlorophenyl)-2,4,5,6-tetrahydrocyclopentapyrazole (I: n = 0, R = SO₂Me, R' = H, R'' = Cl), m.p. 185-7°C (hexane-ethyl acetate)

AFR 404: 2-(4-aminosulphonyl)phenyl-3-(4-chlorophenyl)-2,4,5,6-tetrahydrocyclopentapyrazole (I: n = 0, R = SO₂NH₂, R' = H, R'' = Cl), m.p. 251-3°C (ethyl acetate)

AFR 405: 2-(4-methylsulphonyl)phenyl-3-(3-chloro-4-fluorophenyl)-4,5,6,7-tetrahydroindazole (I: n = 1, R = SO₂Me, R' = Cl, R'' = F), m.p. 187-9°C (hexane-ethanol)

AFR 406: 2-(4-aminosulphonyl)phenyl-3-(3-chloro-4-fluorophenyl)-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{SO}_2\text{NH}_2$, $R' = \text{Cl}$, $R'' = \text{F}$), m.p. 238-240°C (ethanol)

AFR 408: 2-(4-chlorophenyl)-3-(4-methylsulphonyl)phenyl-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{Cl}$, $R' = \text{H}$, $R'' = \text{SO}_2\text{Me}$), m.p. 181-2°C (ethyl acetate)

AFR 500: 2-(4-aminosulphonyl)phenyl-3-(4-methylphenyl)-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{SO}_2\text{NH}_2$, $R' = \text{H}$, $R'' = \text{CH}_3$), m.p. 180-1°C (absolute ethanol)

AFR 507: 2-(4-aminosulphonyl)phenyl-3-(3-chlorophenyl)-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{SO}_2\text{NH}_2$, $R' = \text{Cl}$, $R'' = \text{H}$), m.p. 239-240°C (absolute ethanol)

AFR 508: 2-(4-aminosulphonyl)phenyl-3-(4-methoxyphenyl)-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{SO}_2\text{NH}_2$, $R' = \text{H}$, $R'' = \text{OCH}_3$), m.p. 168-170°C (ethyl acetate)

AFR 601: 2-(4-methylsulphonyl)phenyl-3-phenyl-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{SO}_2\text{Me}$, $R' = R'' = \text{H}$), m.p. 151-2°C (hexane-ethyl acetate)

AFR 602: 2-(4-aminosulphonyl)phenyl-3-phenyl-4,5,6,7-tetrahydroindazole (I: $n = 1$, $R = \text{SO}_2\text{NH}_2$, $R' = R'' = \text{H}$), m.p. 189-191°C (ethanol)

EXAMPLE 4

Preparation of 2-(4-aminosulphonyl)phenyl-3-(4-chlorophenyl)-4,5,6,7-tetrahydroindazole (AFR 101)

(I: $n = 1$, $R = \text{SO}_2\text{NH}_2$, $R' = \text{H}$, $R'' = \text{Cl}$)

By working in a way similar to that described in paragraph a) of Example 3, 1.8 g of the desired product (m.p. 195-197°C, from ethyl acetate) were obtained from 2'-(4-chlorophenyl)spiro[cyclohexane-2'-oxirane]-2-one (2.37 g) (J. Chem. Soc. "Perkin I" page 2435, 1975) and from (4-aminosulphonyl)phenylhydrazine (1.87 g).

- 11 -

Elemental analysis	C	H	N
% found:	58.92	4.64	10.89
% calculated: for $C_{19}H_{18}ClN_3O_2S$	58.83	4.68	10.83

1H -NMR (δ , DMSO): 1.6-2.0 (m, 4H); 2.4-2.8 (m, 4H); 7.1-7.6 (m, 6H+2); 7.8 (d, 2H).

EXAMPLE 5Preparation of 2'-(4-fluorophenyl)spiro[cyclohexane-2'-oxiran]-2-one

(III: A = A', R' = H, R'' = F)

A solution of 30% H_2O_2 (6.54 ml) and, after some minutes, a solution of NaOH 6N (3.1 ml) were dropped into a solution of 2-(4-fluoro)benzylidencyclohexanone (2.8 g, 0.0136 mole) in methyl alcohol (17 ml) under stirring at 10°C. When the dropping was over, after 1 hour at 10°C, the reaction mixture was slowly warmed to room temperature and maintained at this temperature for further 2 hours. After removal of the impurities by filtration, H_2O (50 ml) was added to the limpid solution for precipitating a solid that was dried and crystallized from ethyl acetate (6.5 ml). Yield, 0.9 g (m.p. 137-139°C).

Elemental analysis	C	H
% found:	70.76	5.83
% calculated: for $C_{13}H_{13}FO_2$	70.89	5.95

1H -NMR (δ , $CDCl_3$): 1.2-2.9 (m, 8H); 4.0 (s, 1H); 6.9-7.4 (m, 4H).

EXAMPLE 6Preparation of 2-(4-methylsulphonyl)phenyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydroindazole (AFR 108)(I: n = 1, R = SO_2CH_3 , R' = H, R'' = F)

By working in a way similar to that described in paragraph a) of the previous Example 3, 12.7 g of the desired product (m.p. 183-185°C, from ethyl alcohol) were obtained from 2-(4-fluorophenyl)spiro [cyclohexane-2'-oxirane]-2-one (8.6 g) prepared according to the previous Example 6.

- 12 -

Elemental Analysis	C	H	N
% found:	64.67	5.14	7.54
% calculated: C ₂₀ H ₁₉ FN ₂ O ₂ S	64.85	5.17	7.50

¹H-NMR (δ, DMSO): 1.6-1.9 (m, 4H); 2.4-2.6 (m, 4H); 3.2 (s, 3H); 7.1-7.6 (m, 6H); 7.8 (d, 2H).

EXAMPLE 7

Preparation of 2-(4-methylsulphonyl)phenyl-3-(4-chlorophenyl)-3,3a,4,5,6,7-hexahydroindazole (AFR 109)

(IV; n = 1, R = SO₂CH₃, R' = H, R'' = Cl)

2-(4-chlorobenzyliden)cyclohexanone (6.2 g, 0.028 mole) was added to a solution of (4-methylsulphonyl)phenylhydrazine hydrochloride (6.13 g, 0.024 mole) in absolute ethyl alcohol (200 ml) and, after 1 hour at room temperature, the solution was heated at reflux. After 1 hour, the solution was evaporated under reduced pressure and the residue was taken up with ethyl ether. After filtering, the solid precipitate was crystallized to give 3.3 g of the desired product (m.p. 168-170 °C).

Elemental analysis	C	H	N
% found:	61.94	5.49	7.14
% calculated: for C ₂₀ H ₂₁ ClN ₂ O ₂ S	61.77	5.44	7.20

¹H-NMR (δ, CDCl₃): 0.6-2.5 (m, 7H); 2.7-3.0 (m, 1H); 3.0 (s, 3H); 3.2-3.6 (td, 1H); 5.2 (d, J=12Hz, 1H), 6.8-7.7 (m, 8H).

TEST 1In vitro activity on Cyclooxygenase 1 and 2

The activity of the compounds of formula (I) on cyclooxygenase 1 and 2 was evaluated *in vitro* using cell lines that selectively produce one or the other one enzyme.

As a source of cyclooxygenase 1 (COX1), it was used the U 937 human cell line, while the J 774.2 murine cell line was employed, after lipopolysaccharide (LPS) stimulation, for the cyclooxygenase 2 (COX2). The activity of the compound under evaluation was measured as ability

- 13 -

of inhibiting the transformation of arachidonic acid into prostaglandines (in particular E2 prostaglandin).

In order to analyze the activity on COX1, the U 937 cells were plated at the concentration of 1×10^6 /ml on a Dulbecco's Modified Eagle Medium (DMEM) free of serum and the compound under evaluation was added at the desired concentration (10-0.001 μ M). After incubation for 5 minutes, arachidonic acid was added at the concentration of 10 μ M. The reaction was allowed to run for further 15 minutes. Then, the reaction was stopped by acidifying the medium.

E2 prostaglandines, produced and released into the supernatant, were then counted by a commercially available (AMERSHAM) specific immune enzymatic test.

In order to evaluate the activity on COX2, the J 774.2 cells were treated with aspirin (300 μ M) for 1 hour and then incubated with LPS (1 μ M) for 12 hours. Afterwards, it was utilized the same procedure as described for U 937 except that arachidonic acid was not added.

The results of the tests are shown in Table 1:

TABLE 1

Compound	Concentration (μ M)	% Inhibition	
		COX1	COX2
indomethacin	10	82	-
	1	79	-
	0.1	69	-
AFR 408	10	0	89
	1	0	70
	0.1	0	26
AFR 405	10	0	57
	1	0	42
	0.1	3	35
AFR 406	10	55	60

- 14 -

	1	0	63
	0.1	12	44
AFR 500	10	38	69
	1	0	61
	0.1	0	25
AFR 206	10	3	72.9
	1	19	50.7
	0.1	14	4.9
AFR 207	10	39	76.3
	1	6	69.1
	0.1	16	17.6
AFR 209	10	1	6.5
	1	12	9.8
	0.1	3	27.0
AFR 402	10	0	63
	1	0	58
	0.1	0	36
AFR 404	10	42	71
	1	6	65
	0.1	19	48
AFR 101	10	77	83
	1	41	58
	0.1	0	25
AFR 507	10	83	73
	1	48	50
	0.1	58	7
AFR 508	10	44	70
	1	16	40
	0.1	13	12

- 15 -

AFR 906	10	17	77
	1	20	60
	0.1	16	35

TEST 2Anti-inflammatory activity

The anti-inflammatory activity of AFR 906 and AFR 101 was evaluated according to the test of the inhibition of edema induced by carrageenin inoculation (50 µl of 1% suspension in physiologic solution) in a rat leg. AFR 906 and AFR 101 were administered orally at 30 min. from inoculation of the irritant agent at the concentration of 6.25 mg/Kg.

Indomethacin (2 mg/kg p.o.) was used as comparison product.

The test was carried out by using 12 animals for each group of treatment. The activity was evaluated by measuring the volume increase of the leg with a pletismometer.

The result of the test are shown in Table 2.

TABLE 2

	basal	30'	1h	2h	4h	6h
controls	0.82	0.96	1.04	1.31	1.46	1.35
AFR 101 (6.25)	0.83	0.95	1.01	** 1.15	** 1.25	** 1.20
AFR 906 (6.25)	0.82	0.94	0.98	** 1.16	** 1.24	** 1.21
indomethacin (2)	0.82	0.91	* 0.92	** 1.09	** 1.19	1.25

TEST 3Analgesic activity

The activity of AFR 906 and AFR 101 were evaluated with the Randall & Selitto procedure by testing the pain test caused by a pressure on the inflamed rat leg. Pain was measured with an analgesimeter as the pressure (grams) that, applied to the inflamed leg, caused the animal to react.

The inflammatory hyperalgesia was induced by injecting brewer yeast (5%) under skin into the left leg of the rat. AFR 906 and AFR 101

- 16 -

were administered intraperitoneally at a dose of 12.5 mg/kg, 2 hours after the yeast administration.

The test was carried out by using 6 animals for each group of treatment. Indomethacin (2 mg/kg i.p.) was used as comparison drug. The activity of the compound under evaluation was measured as ability to rise the pain threshold.

The results of the test are shown in Table 3.

TABLE 3

Compound	Dosage (mg/Kg i.p.)	Relief (average \pm D.S.)	
		basal	+ 3 h from yeast
control	-	177 \pm 19	159 \pm 14
indomethacin	2	177 \pm 22	270 \pm 51**
AFR 906	12.5	177 \pm 21	216 \pm 36*
AFR 101	12.5	175 \pm 21	274 \pm 44**

** p < 0.01, * p < 0.05 compared to the control.

TEST 4

Activity on gastric mucosa

The ulcerogenic activity of AFR 906 and AFR 101 were evaluated on the gastric mucosa of rats treated by oral route with a single administration (6.25, 12.5, 100 and 200 mg/kg) of the compounds under evaluation.

Indomethacin was used as comparison drug (5 and 10 mg/kg).

After treatment, the animals (7-9 in each group) were maintained on an empty stomach for 17 hours (with free access to water) and then sacrificed. The gastric mucosa was examined to value the possible presence of lesions that were classified with a score of from 0 to 4 depending on the severity.

The results of the test are shown in Table 4.

- 17 -

TABLE 4

Compound	Dosage (mg/Kg p.o.)	rats with ulcer (%)	lesions severity (score average in animals with ulcers)
AFR 906	6.25	0	0
	12.50	0	0
	100.00	0	0
	200.00	0	0
AFR 101	200.00	38	1.7
	50.00	20	2
indomethacin	5.00	14	3
	10.00	86	3.5

TEST 5Systemic toxic effects


Systemic toxicity of AFR 906 and AFR 101 were valued in rat according to a variation of the Irwin test. The AFR 906 compound is devoid of behavioural and toxic effects up to a dose of 800 mg/Kg after intraperitoneal and oral administration.

The first toxic effects of AFR 101 (such as, for example, reduction of spontaneous activity, non coordination of movements and reduction of respiratory rate) become manifest at a dose of about 400 mg/Kg by both intraperitoneal and oral route.

100% of treated animals showed lethal effects at a dose of 800 mg/Kg via intraperitoneal route.

CLAIMS

1. A pharmaceutical composition comprising a diaryl-cyclomethylenpyrazole of formula




(I)

wherein

n is 0, 1, 2 or 3;

R, R' and R'', equal or different each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl or a pharmaceutically acceptable salt thereof, together with at least a pharmaceutically acceptable carrier.

2. A diaryl-cyclomethylenpyrazole of formula



(Ia)


wherein

n is 0, 1, 2 or 3;

R, R' and R'', equal or different each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl, or pharmaceutically acceptable salts thereof, provided, however, that

- 19 -

- a) when n is 1, and two of R, R' and R'' are hydrogen, the third is not hydrogen or chlorine; and
- b) when n is 3, at least one of R, R' and R'' is not hydrogen.
3. A compound according to claim 2, wherein n is 0, 1 or 2.
 4. A compound according to claim 2 or 3, wherein halogen is fluorine or chlorine.
 5. A compound according to any one of claims of from 2 to 4, wherein the alkyl chain of the alkylsulphonyl and alkylamino sulphonyl has of from 1 to 6 carbons.
 6. A compound according to any one of claims of from 2 to 4, wherein the alkyl chain of the alkylsulphonyl and alkylamino sulphonyl has of from 1 to 3 carbons.
 7. A compound according to any one of claims of from 2 to 6, wherein the alkyl chain is methyl or cyclopropyl.
 8. A process for preparing a compound of formula (I)




(I)

wherein

n is 0, 1, 2 or 3;


R, R' and R'', equal or different each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl, or pharmaceutically acceptable salts thereof, wherein a compound of formula

- 20 -




where X is H or cycloesilidene , and

R has the above mentioned meanings, is reacted with a compound of formula



where R and R'' have the above mentioned meanings and A is selected from the group comprising COHal, A', A'' and A'''




where Hal is halogen,

and, when desired, the so obtained compound of formula (I) is transformed into a pharmaceutically acceptable salt thereof.

9. A process according to claim 8, characterized in that, when X = H, this reaction is carried out in a solution of a suitable polar diluent and in the presence of an organic or mineral acid at a temperature of from 0 to 120°C.
10. A process according to claim 9, characterized in that the reaction is carried out at a temperature of from 60 to 80°C.
11. A process according to any one of claims 9 and 10, characterized in that the diluent is a lower aliphatic alcohol.


- 21 -

12. A process according to claim 11, characterized in that, when $A = A'$ and X is hydrogen, the reaction is carried out in the presence of glacial acetic acid.
13. A process according to claim 11, characterized in that when $A = A''$ and X is hydrogen, the reaction is carried out in the presence of sulphuric acid.
14. A process according to claim 11, characterized in that when $A = A'''$ and X is hydrogen, the reaction is carried out in the presence of hydrochloric acid, to give the compound of formula (IV)



from which the corresponding compound of formula (I) is prepared by treating with a weak oxidant.


15. A process according to claim 14, characterized in that the weak oxidant is bromine in water.
16. A process according to claim 8, characterized in that, when A is COHal and X is cyclohexylidene, the reaction is carried out in the presence of anhydrous tetrahydrofuran at a temperature of from -70°C to 20°C .
17. An intermediate compound of formula



wherein

- 22 -


A is



and

R' is H, Cl or F and R'' is alkylsulphonyl or fluorine, or


A is



and

R' is H and R'' is alkylsulphonyl.


18. A compound according to claim 17, wherein the alkylsulphonyl is methylsulphonyl.
19. An intermediate compound of formula



(V)

wherein R' is H and R'' is alkylsulphonyl.

20. A compound according to claim 19, wherein the alkylsulphonyl is methylsulphonyl.
21. An intermediate compound of formula



(IV)

- 23 -

wherein $n = 1$, R is metylsulphonyl, R' is hydrogen and R'' is chlorine.




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 231/54, A61K 31/415, C07D 303/32, C07C 317/24	A3	(11) International Publication Number: WO 98/22442 (43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/EP97/06398 (22) International Filing Date: 12 November 1997 (12.11.97) (30) Priority Data: MI96A002385 15 November 1996 (15.11.96) IT (71) Applicant (for all designated States except US): ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE [IT/IT]; Pi- azzale della Stazione, I-00040 S. Palomba - Pomezia (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): GIANNANGELI, Marilena [IT/IT]; Via Clelia, 88, I-00181 Roma (IT). TOMASELLI, Mauro [IT/IT]; Via Leibniz, 28, I-00137 Roma (IT). PINZA, Mario [IT/IT]; Via per Cesano Boscone, 24, I-20094 Corsico (IT). (74) Agents: MARCHI, Massimo et al.; Marchi & Partners s.r.l., Via Pirelli, 19, I-20124 Milano (IT).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 30 July 1998 (30.07.98)

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING DIARYL-CYCLOMETHYLENOPYRAZOLE COMPOUNDS AND THEIR USE AS CYCLOOXYGENASE I (COX 1) INHIBITORS

(57) Abstract

A pharmaceutical composition comprising a diaryl-cyclomethylenpyrazole compound of formula (I) wherein n is 0, 1, 2 or 3; R, R' and R'', equal to or different from each other, are H, halogen, alkylsulphonyl, aminosulphonyl and alkylaminosulphonyl, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/06398

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D231/54 A61K31/415 C07D303/32 C07C317/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. HETEROCYCL. CHEM., vol.10, no.5, October 1973 pages 763 - 767, XP002032956 BAUMES R ET AL 'Sur une prétendue forme NH stable d'une pyrazoline-3' see page 763, column 2, last paragraph ---	8
A	PESTICIDE SCIENCE, vol.42, no.1, 1 September 1994 pages 29 - 36, XP000478711 LYGA J W ET AL 'SYNTHESIS, MECHANISM OF ACTION, AND QSAR OF HERBICIDAL 3-SUBSTITUT ED-2-ARYL-4,5,6,7-TETRAHYDROINDAZOLES' see page 31; column 1, figure 7 --- -/--	8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

16 March 1998

Date of mailing of the international search report

29. 05. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

FINK D.G.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/06398

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 084, no. 13, 29 March 1976, Columbus, Ohio, US; abstract no. 090060, OZOLINS J ET AL 'Reaction of 2-aroyl-1-cyclohexanones and their 6-amino derivatives with hydrazines' * see abstract; and Chemical Abstract, CHEMICAL SUBSTANCES, 9th Collective Index, vol. 76-85, 1972-1976, page 19574CS, column 1, the compounds with the RN: [58413-29-9] and [58413-30-2]; and column 3, the compounds with the RN: [58413-22-2] and [58413-23-3] * & KHIM. GETEROTSIKL. SOEDIN. 1975(11); PP.1545-9 ---	8
A	WO,A,95 15316 (G D SEARLE & CO) 8 June 1995 see page 184 - page 187; claim 1 see page 7, line 8 - page 8, line 16 see page 144 - page 145; example 187 ---	1-7, 16-21
A	EP,A,0 015 156 (E R SQUIBB & SONS, INC) 3 September 1980 see the whole document ---	1-7, 16-21
A	US,A,3 928 378 (V J BAUER ET AL) 23 December 1975 see the whole document ---	1-7, 16-21
A	DE,A,26 30 015 (SOCIETE D'ETUDES ET DE RECHERCHES ENZYMOLOGIQUES ET PHARMACOLOGIQUES) 27 January 1977 see the whole document -----	1-7, 16-21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 97/ 06398

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. claims: 1-7, 8-16(partly), 17-21
2. claims: 8-16(partly)

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7, 8-16(partly), 17-21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/06398

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515316 A	08-06-95	US 5466823 A	14-11-95
		US 5521207 A	28-05-96
		AU 1171495 A	19-06-95
		CA 2177576 A	08-06-95
		CN 1141630 A	29-01-97
		CZ 9601503 A	11-12-96
		EP 0731795 A	18-09-96
		FI 962249 A	29-05-96
		HU 74180 A	28-11-96
		JP 9506350 T	24-06-97
		NO 962184 A	29-05-96
		PL 314695 A	16-09-96
		US 5510496 A	23-04-96
		US 5563165 A	08-10-96
		US 5508426 A	16-04-96
		US 5516907 A	14-05-96
		US 5504215 A	02-04-96
		ZA 9409418 A	28-11-95

EP 0015156 A	03-09-80	US 4173634 A	06-11-79
		AU 5528380 A	28-08-80
		JP 55115871 A	06-09-80
		ZA 8000670 A	25-02-81

US 3928378 A	23-12-75	NONE	

DE 2630015 A	27-01-77	FR 2315924 A	28-01-77
